Institution identification

PURI

https://redirect.ema.europa.eu/resource/104338

Institution ID

104338

Institution full name and acronym

ICON Commersialisation & Outcomes (MAPI-ICON), ICON

Institution countries

Germany

Type of institution

Non-Pharmaceutical company

Institution website

ENCePP partner

Yes
Institution description
To partner with our sponsors,the scientific community,healthcare providers and patients to conduct quality research,advance scientific knowledge,gain clinical insights,and optimize the effectiveness and safety of medical products.
Institution details
Experience with collecting data directly from individual patients or respondents:
Yes
Interest in carrying out research that is funded by pharmaceutical companies:
Yes

Contact

Studies conducted by the institution

A Cross-sectional Study Among Healthcare Professionals in Canada to Assess Awareness and Knowledge of the Fibristal Additional Risk Minimization Measures
A Cross-sectional Study Among Patients in Canada to Assess Awareness and Knowledge of the Fibristal Patient Alert Card
A cross-sectional study to evaluate the effectiveness of XALKORI Patient Information Brochure among non-small cell lung cancer (NSCLC) patients receiving XALKORI treatment in Europe
A cross-sectional study to evaluate the effectiveness of XALKORI Therapeutic Management Guide among physician prescribing XALKORI in Europe
A Non-interventional Post-authorisation Safety Study (PASS) as an Effectiveness Check of the Prescriber Checklist for Mycamine® (micafungin)
A Survey of Healthcare Professionals in Europe to Evaluate the Effectiveness of the ENJAYMO™ Physician’s Guide
A THAOS Sub-Study Evaluating the Effects of Tafamidis on Disease Progression in Patients with non-V30M Mutations and Symptomatic Neuropathy
An Observational Prospective Long-term Exposure Registry of Adult Patients With Moderate-to-Severe Ulcerative Colitis (OPAL)
Drug Utilization of Boceprevir and Clinical Management of Health Outcomes of Interest in Chronic Hepatitis C Patients (P08518)
Effectiveness evaluation survey for Eurartesim
Evaluation of the Effectiveness of a Xospata Routine Risk Minimisation Measure (RMM) and an Additional Risk Minimisation Measure (aRMM): A Cross-sectional Survey Study among Healthcare Professionals to Assess Awareness and Knowledge
Exposure to pioglitazone and the risk of prostate cancer: a nested case-control study
Pharmaco-epidemiologic study on occurrence of adverse events
Pregnancy Registry for Eurartesim
Safety registry for Eurartesim